Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study.

Blanquer, José; Blanquer, Rafael; Borrás, Rafael; Nauffal, Dolores; Morales, Pamela S.; Menéndez, Rosário; Subías, I; Herrero, Lorenza Alvarez; Redón, Josep; Pascual, J.M.

doi:10.1136/thx.46.7.508

Cited by 125 publications

(73 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One reason for such a low rate of P. aeruginosa may have been the exclusion of nursing home patients, identifying a need for the re-evaluation of recommendations for group IVb patients when this population excludes those with HCAP. The mortality rates obtained in the present study were similar to those reported by other researchers [29,30]. However, it was found that nonadherence to ATS guidelines was associated with a more than doubling of mortality, although this was not significant on multivariate analysis.…”

Section: Discussionsupporting

confidence: 90%

Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome

Dambrava

Torres²,

Vallès³

et al. 2008

European Respiratory Journal

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome

Dambrava

Torres²,

Vallès³

et al. 2008

European Respiratory Journal

View full text Add to dashboard Cite

“…Influenza viruses can be classified as A, B or C. Influenza A is found in humans, other mammals and birds, and is the only influenza virus known to have caused pandemics, such as the three twentieth century pandemics and the current influenza pandemic of swine origin [2]. Although the greatest proportion of mortality caused by influenza A infection is due to secondary bacterial pneumonia, the virus itself is also an important cause of community-acquired pneumonia (CAP), causing 5-10% of CAP in various case series [3,4]. As such, influenza infection is a major concern for pulmonologists and intensive care physicians.…”

mentioning

confidence: 99%

Factor V Leiden mutation does not affect coagulopathy or outcome in lethal H1N1 influenza

Schouten

Sluijs²,

Roelofs³

et al. 2010

European Respiratory Journal

View full text Add to dashboard Cite

Influenza A is a major cause of mortality. Knowledge on coagulation activation in influenza infection is limited. The factor V Leiden (FVL) mutation is possibly subject to positive selection pressure. It is unknown whether this mutation impacts on the outcome of severe influenza. In the present study, the effect of lethal influenza on pulmonary and systemic coagulation activation and whether or not FVL mutation alters coagulation activation in and the course of lethal influenza, was determined.Wild-type mice, and mice heterozygous or homozygous for FVL were infected intranasally with a lethal dose of H1N1 (haemagglutinin 1 and neuraminidase 1) influenza A. Mice were sacrificed after 48 or 96 h for determination of coagulation activation, histopathology, pulmonary inflammatory parameters and viral load, or were observed in a survival study.Extensive local and systemic coagulation activation during lethal influenza was demonstrated by increased lung and plasma levels of thrombin-antithrombin complexes and fibrin degradation products, and by pulmonary fibrin deposition. FVL mutation did not influence the procoagulant response, lung histopathology or survival. FVL mice demonstrated elevated viral loads 48 h after infection.In conclusion, coagulation is activated locally and systemically during lethal murine influenza A infection. The FVL mutation does not influence coagulation activation, lung inflammation or survival in lethal influenza A.

show abstract

“…Recent observational studies have shown P. aeruginosa to be a rare cause of CAP and the etiologic microbe in 1% to 5% of patients with CAP (12)(13)(14)(15). On the other hand, P. aeruginosa has been reported to be the cause of severe CAP (CAP necessitating admission to the ICU or causing shock) in 1.8% to 8.3% of patients, with a case-fatality rate of 50% to 100% (16)(17)(18)(19).…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Fulminant Community-Acquired <i>Pseudomonas aeruginosa</i> Necrotizing Pneumonia in a Previously Healthy Young Man

et al. 2012

View full text Add to dashboard Cite

This report presents a case of fulminant community-acquired Pseudomonas aeruginosa necrotizing pneumonia in a previously healthy young man, including an analysis of the virulence of the P. aeruginosa isolated from the patient. The patient was successfully treated with intensive care and antibiotic treatment. This study analyzed the pathogenicity of the isolated strain both in vivo (using a mouse pneumonia model) and in vitro (using biofilm production), but could not explain how an otherwise healthy young man developed such severe community-acquired P. aeruginosa pneumonia. Although rare in community-acquired pneumonia, P. aeruginosa infection should be considered in patients with severe rapidly progressive pneumonia.

show abstract

Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study.

Cited by 125 publications

References 24 publications

Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome

Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome

Factor V Leiden mutation does not affect coagulopathy or outcome in lethal H1N1 influenza

Successful Treatment of Fulminant Community-Acquired <i>Pseudomonas aeruginosa</i> Necrotizing Pneumonia in a Previously Healthy Young Man

Contact Info

Product

Resources

About